Corvus Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on June 11, 2026. The record date for the meeting was April 16, 2026, with 84,090,424 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
A total of 73,021,854 shares were voted in person or by proxy. The outcomes for the three proposals were as follows:
- Proposal 1 (Election of Directors): Stockholders elected Class III director nominees Richard A. Miller, M.D., and Linda S. Grais, M.D., J.D. to serve until the 2029 Annual Meeting. Significant broker non-votes (12,049,623) were recorded for this proposal.
- Proposal 2 (Ratification of Accounting Firm): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items beyond the standard voting procedures.
Key Facts for Investor Verification
- Verify the full slate of director nominees and their qualifications in the Definitive Proxy Statement (Schedule 14A) filed on April 24, 2026.
- Review the specific compensation details for named executive officers referenced in Proposal 3.
- Confirm the scope of services and fees associated with the ratification of PricewaterhouseCoopers LLP.
- Note the high volume of broker non-votes (12,049,623) on the director election and executive compensation proposals.